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changes in substrate selectivity in exemplar APC amino 
acid transporters including PAT2 (SLC36A2) and SNAT5 
(SLC38A5). Our work demonstrates how a single residue/
site within an archetypal structural motif can alter substrate 
affinity and selectivity within this important superfamily of 
diverse membrane transporters.
Keywords Amino acid · Transporter · Membrane 
transport · LeuT · APC superfamily · SLC
Introduction
For any eukaryotic or prokaryotic cell to remain viable, it 
must express a large and diverse complement of membrane 
transport proteins to enable import and export, between the 
cell and the local environment, of all material vital for life. 
Carrier-mediated, transmembrane amino acid transport is 
essential in neurotransmission, nutrient absorption from 
diet, osmoregulation, and in the supply of components for 
protein synthesis, nitrogen metabolism, cell growth, energy 
production, and conversion. Thus, each cell type possesses 
a unique array of amino acid transporters to permit optimal 
physiological performance within any given milieu.
The largest collection of amino acid transporters across 
all forms of life is found within the Amino acid-Polyam-
ine-organoCation (APC) superfamily [Transporter Classi-
fication DataBase (TCDB)] [1, 2]. Substrates include the 
20 proteinogenic amino acids (which differ in size, shape, 
hydrophobicity, polarity, and charge on the α carbon side-
chain), non-proteinogenic α amino acids (e.g., betaine and 
ornithine), and unbranched chain amino acids and analogues 
where the amino group is in the β or γ position (e.g., tau-
rine, GABA). Carriers vary greatly in substrate specificity 
with some transporting a single type of amino acid (with 
Abstract Amino acid transporters are essential compo-
nents of prokaryote and eukaryote cells, possess distinct 
physiological functions, and differ markedly in substrate 
specificity. Amino acid transporters can be both drug targets 
and drug transporters (bioavailability, targeting) with many 
monogenic disorders resulting from dysfunctional mem-
brane transport. The largest collection of amino acid trans-
porters (including the mammalian SLC6, SLC7, SLC32, 
SLC36, and SLC38 families), across all kingdoms of life, 
is within the Amino acid-Polyamine-organoCation (APC) 
superfamily. The LeuT-fold is a paradigm structure for APC 
superfamily amino acid transporters and carriers of sugars, 
neurotransmitters, electrolytes, osmolytes, vitamins, micro-
nutrients, signalling molecules, and organic and fatty acids. 
Each transporter is specific for a unique sub-set of solutes, 
specificity being determined by how well a substrate fits 
into each binding pocket. However, the molecular basis of 
substrate selectivity remains, by and large, elusive. Using 
an integrated computational and experimental approach, we 
demonstrate that a single position within the LeuT-fold can 
play a crucial role in determining substrate specificity in 
mammalian and arthropod amino acid transporters within 
the APC superfamily. Systematic mutation of the amino 
acid residue occupying the equivalent position to LeuT 
V104 titrates binding pocket space resulting in dramatic 
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extreme selectivity), others accepting almost all amino acids 
(with varying levels of discrimination), with most falling 
somewhere in between. This commonality in general func-
tion (amino acid transport), but heterogeneity in substrate 
selectivity, provoked this investigation into the molecular 
basis of carrier diversity.
The solution of the three-dimensional structure of the 
Aquifex aeolicus  Na+/amino acid cotransporter LeuT opened 
a window into our understanding of APC transporter biology 
not only in prokaryotes but also in eukaryotes [3]. LeuT was 
the first APC superfamily member to be solved at atomic 
level [3], but others have followed including carriers of 
amino acids, biogenic amines, divalent metals, monosaccha-
rides, organocations, and osmolytes [4–16]. Although these 
APC carriers differ in both substrate selectivity and transport 
mechanism (functioning as symporters or antiporters, and 
being driven by ionic or solute gradients), it is striking that 
they possess a similar structure, known commonly as the 
LeuT-fold [3–17]. This large APC superfamily possesses; 
therefore, a universal core skeleton for which the LeuT struc-
ture can be considered an archetype [18, 19].
Mammalian LeuT-fold APC transporters are also classi-
fied, based upon sequence identity, into eight solute carrier 
(SLC) families (SLCs 5, 6, 7, 11, 12, 32, 36, and 38), in 
accordance with the Human Gene Organisation (HUGO) 
Gene Nomenclature Committee (HGNC) [20]. Seventy-
one distinct human SLCs are predicted to possess the LeuT 
structural-fold. They vary widely in substrate selectivity 
and include transporters of amino acids, sugars, neurotrans-
mitters, vitamins, electrolytes, micronutrients, signalling 
molecules, and organic and fatty acids. Interpretation of 
the prokaryote LeuT crystal structure, relative to function, 
was aided extensively by the earlier structure–function stud-
ies of mammalian SLC6 transporters involved in transport 
of the neurotransmitters GABA, serotonin, dopamine, and 
noradrenaline [21–24]. In turn, near-atomic resolution struc-
tures, such as the 1.65 Å LeuT structure [3], yield great 
insight into the workings of distantly related mammalian 
solute carriers [18, 19].
Structures of LeuT-fold transporters exhibit a conserved 
binding environment. For example, comparison of three 
sequence-unrelated prokaryotic APC superfamily trans-
porters, LeuT [from the Neurotransmitter:Sodium Sym-
porter family (NSS, TCDB family 2.A.22)], the arginine/
agmatine antiporter AdiC [from the Amino Acid-Polyamine-
Organocation (APC, 2.A.3) family], and the  Na+/benzyl-
hydantoin cotransporter Mhp1 [from the Nucleobase:Cation 
Symporter-1 (NCS1, 2.A.39) family], demonstrate that sub-
strates sit within the occluded structures in the same general 
locale [3, 9, 25]. Despite this strong structural consensus, 
the substrate selectivity of each carrier type remains unique.
LeuT-like structures contain a core of ten transmembrane 
(TM) spans, organised into a 5 + 5 inverted structural repeat, 
with TM1, 3, 6, and 8 forming the central binding pocket of 
each carrier [3–17]. In the original LeuT structure, the ali-
phatic side-chain of the substrate sits within a hydrophobic 
pocket formed from the side-chains of residues in TM3, 6, 
and 8 [3]. Comparative modelling of LeuT with more than 
300 prokaryotic and eukaryotic NSS sequences identified 
that the residues that interact with the substrates’ side-chains 
in the deeper regions of the binding pockets are not con-
served [26]. Bioinformatics analyses, using functional site 
prediction strategies, anticipated key functional sites within 
the NSS family and correctly predicted 31/34 substrate-
interacting residues in the LeuT structure [27]. Residues in 
the three “non-predicted” positions in LeuT all form van der 
Waals’ contacts with the substrate side-chain [3]. LeuT was 
subsequently crystallised bound to a series of amino acids 
with increasing side-chain size [28]. When LeuT is locked in 
the outward-open substrate-bound conformation, by interac-
tion with the large indole ring of the non-transported inhibi-
tor tryptophan [28], V104 in TM3, one of the non-conserved 
residues identified in the bioinformatics analyses [26, 27], 
and the focus of the current investigation, occupies a deep 
position below the indole ring.
An ambition of global industry is to use in silico method-
ology to predict drug delivery, action of novel pharmaceu-
ticals, and utilisation and efficiency of new agrichemicals. 
Ultimately, to achieve such an understanding of the roles 
of individual transporters in these essential functions, it is 
necessary to determine how the identity of amino acid resi-
dues coordinating the substrates within the binding pocket 
of each APC superfamily carrier defines substrate specific-
ity. Here, we investigated the hypothesis that amino acid 
residues occupying the equivalent position to V104 in the 
LeuT-fold of APC carriers are critical in governing substrate 
specificity. The basis of substrate selectivity in LeuT-fold 
APC superfamily amino acid transporters was investigated 
using a series of wild-type and mutated transporters from 
the important Amino Acid/Auxin Permease (AAAP, 2.A.18) 
family [2, 29], which are expressed ubiquitously in plants, 
animals, yeast, and fungi. The relationship between different 
amino acid transporter families within the APC superfamily 
was investigated by computational phylogenetic methodol-
ogy. Structural models were constructed based upon the out-
ward-occluded substrate-bound conformations of the APC 
superfamily members LeuT, AdiC, and Mhp1 [3, 9, 25]. 
Site-directed mutagenesis and functional measurements of 
transporter activity were used to validate the structural mod-
els in multiple AAAP transporters. Excellent agreement was 
observed between model predictions and functional activity. 
In addition, re-evaluation of published data on non-amino 
acid transporting APC carriers suggests that the site inves-
tigated has an importance in defining substrate specificity 
beyond amino acid transporters. Taken together, our results 
demonstrate how a single residue/site within an archetypal 
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Fig. 1  Phylogenic analysis of the APC superfamily including rep-
resentative sequences from all major APC families whose trans-
port proteins are predicted to possess the LeuT-fold 5  +  5 inverted 
structural repeat. The 14 families are the: Amino Acid-Polyamine-
Organocation (APC) family (TC# 2.A.3), which includes the mam-
malian SLC7 family; Betaine/Carnitine/Choline Transporter (BCCT) 
family (2.A.15); Amino Acid/Auxin Permease (AAAP) family 
(2.A.18), including mammalian SLC32, SLC36 and SLC38 families; 
Solute:Sodium Symporter (SSS) family (2.A.21), including the mam-
malian SLC5 family; Neurotransmitter:Sodium Symporter (NSS) 
family (2.A.22), including the mammalian SLC6 family; Alanine or 
Glycine:Cation Symporter (AGCS) family (2.A.25); Branched Chain 
Amino Acid:Cation Symporter (LIVCS) family (2.A.26); Cation-
Chloride Cotransporter (CCC) family (2.A.30), including the mam-
malian SLC12 family; Nucleobase:Cation Symporter-1 (NCS1) fam-
ily (2.A.39); Hydroxy/Aromatic Amino Acid Permease (HAAAP) 
family (2.A.42); Metal Ion  (Mn2+-iron) Transporter (Nramp) family 
(2.A.55), including the mammalian SLC11 family;  K+ Uptake Per-
mease (KUP) family (2.A.72); Putative Peptide Transporter Car-
bon Starvation CstA (CstA) family (2.A.114); Putative Amino Acid 
Permease (PAAP) family (2.A.120). The position of PAT2 (TC# 
2.A.18.8.2) is indicated by asterisk. Example transporters with 
known atomic structures (included in the TCDB) are denoted: AdiC 
of E. coli (2.A.3.2.5); ApcT of M. jannaschii (2.A.3.6.3); GadC of 
E. coli (2.A.3.7.3); BetP of C. glutamicum (2.A.15.1.10); CaiT of E. 
coli (2.A.15.2.1) and P. mirabilis (2.A.15.2.2); vSGLT of V. para-
haemolyticus (2.A.21.3.2); SERT of H. sapiens (2.A.22.1.1); DAT 
of D. melanogaster (2.A.22.1.7); LeuT of A. aeolicus (2.A.22.4.2); 
MhsT of B. halodurans (2.A.22.5.3); and Mhp1 of M. liquefaciens 
(2.A.39.3.6). In addition, there are several crystals from the Nramp 
(2.A.55) family (not shown). DraNramp (MntH) of D. radiodurans 
(2.A.55.3.7) has recently been added to the TCDB. The phylogeny 
was generated using the CAT20 model in PhyloBayes. Each branch, 
representing an individual transporter sequence, is identified by the 
appropriate TCDB number (see list of sequences in supplementary 
Table S1). Values at branches represent posterior probabilities (scale 
bar: average number of substitutions per site). The majority of APC 
families are well supported as clans. Three sequences branch sepa-
rately from their annotated family but are located close to the base of 
the tree with very weak support, suggesting that their position is an 
artefact due to long-branch attraction
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structural motif alters substrate affinity and selectivity in an 
extensive, widely distributed and important superfamily of 
cellular transport proteins.
Materials and methods
Materials
Radiolabelled amino acids were from GE Healthcare Life 
Sciences (Little Chalfont, UK), PerkinElmer (Beaconsfield, 
UK), Hartmann Analytic (Braunschweig, Germany), and 
American Radiolabeled Chemicals (St. Louis, USA). In vitro 
transcription reagents were from Promega (Southampton, 
UK) or Ambion (Warrington, UK). Site-directed mutagen-
esis QuikChange Lightning kit, reagents, and primer design 
were from Agilent Technologies (Stockport, UK).
Phylogeny
Sequences for the APC superfamily tree were retrieved 
from the TCDB [1]. An initial selection of sequences 
included TCDB entries (denoted TC#) with structural data 
plus TCDB entries with strong functional characterisation. 
Additional sequences were added to improve both the taxo-
nomic diversity of the sampling and to cover additional APC 
families. Human sequences for SLCs 5, 6, 7, 11, 12, 32, 36, 
and 38 were retrieved via the Bioparadigms database [20]. 
Additional sequences (rat, mouse, rabbit, Drosophila mela-
nogaster, Aedes aegypti, and Acyrthosiphon pisum) were 
from NCBI and were included for reference. All sequences 
were aligned using MUSCLE [30]. The alignment was 
trimmed using TrimAl v1.4 [31], with trimming param-
eters defined by the automated1 option. Phylogenies were 
generated in PhyloBayes [32] using the CAT20 model [33]. 
Trimmed (and untrimmed) sequence alignments associated 
with the phylogenies are available at figshare using the link: 
https://figshare.com/s/378479b6958df7816b1b.
Threading, alignment, and homology modelling
HHPred [34] and Modeller [35] were used (using default 
settings) (http://www.toolkit/tueingen/mpg.de) to derive 
alignments and model eukaryotic and prokaryotic transport-
ers based on the substrate-bound, outward-occluded, crystal 
structures of the following prokaryotic transport proteins: the 
 Na+/amino acid cotransporter LeuT from A. aeolicus (bound 
to leucine, 1.65 Å resolution, protein data bank (PDB) ID 
2A65) [3], the arginine/agmatine antiporter AdiC from E. 
coli (bound to arginine, 3.0 Å resolution, 3L1L) [9], and the 
 Na+-coupled benzyl-hydantoin transporter Mhp1 from M. 
liquefaciens (bound to 5-indolylmethyl-l-hydantion, 3.4 Å 
resolution, 4D1A) [25]. In addition, other APC transporter 
structures were used including: LeuT (3F48), DAT (4XP4), 
AdiC (5J4I), ApcT (3GIA), and Mhp1 (2JLN) [5, 6, 12, 28]. 
For rat PAT2, HHPred probability scores were 95.7, 99.9, 
and 99.2% for predicted structural homology to LeuT, AdiC, 
and Mhp1, respectively, with most APC crystal structures 
scoring > 90%. PROMALS3D [36] was used (using default 
settings) for multi-alignments of crystal structure sequences 
with rat PAT2 and to confirm the results produced using 
other methods. The I-TASSER server (http://zhanglab.ccmb.
med.umich.edu/) [37] was used (with default settings) for 
threading and modelling of the rat PAT2 sequence to gener-
ate a consensus model and to compare alignments with those 
produced by HHPred [34] and PROMALS3D [36]. Multi-
ple structure–structure alignments of LeuT (2A65, 3F48), 
AdiC (3L1L, 5J4I), Mhp1 (2JLN, 4D1A), ApcT (3GIA), and 
the I-TASSER-derived PAT2 model were performed using 
Matt [38]. All approaches were also used to identify residues 
equivalent to LeuT V104 and rat PAT2 F159. Structures and 
models were visualised, and figures prepared, using PyMOL.
Plasmid constructs and site‑directed mutagenesis
The use of plasmid constructs for rat PAT2 (SLC36A2) and 
human SNAT5 (SLC38A5) in pSPORT1, and mouse PAT1 
(SLC36A1) in pCRII-TOPO, has been described previously 
[39–41]. The Drosophila transporter CG1139 was purchased 
from the Drosophila Genomics Resource Centre (Indiana 
University, USA) and expressed in pGH19 (gift from G. 
Robertson, University of Wisconsin, USA). Site-directed 
mutagenesis was performed using the QuikChange Light-
ning kit, according to the manufacturer’s instructions. The 
PCR cycling parameters used were an initial 2 min incuba-
tion at 95 °C, followed by: 18 cycles at 95 °C denaturation 
(20 s); 68 °C annealing (10 s); 68 °C extension (30 s kb−1 
plasmid); and a final extension at 68 °C for 5 min. Parental 
plasmid DNA was digested with DpnI and the PCR reaction 
product used to transform XL-10 Gold cells. Oligonucleo-
tides were designed using the QuikChange primer design 
tool. Mutations were verified by sequencing (GATC Biotech, 
London, UK) of the entire open reading frame.
Functional expression in Xenopus laevis oocytes
Plasmid DNA was linearised by HindIII (PAT1, PAT2, 
and CG1139) or NotI (SNAT5), and used as a template 
for cRNA synthesis using the T7 mMessage mMachine 
kit (Thermo Fisher, Cramlington, UK) or as follows: lin-
ear DNA (< 3.5 μM) was incubated with T7 polymerase 
(50U), dNTPs, RNase inhibitor (160U), reaction buffer, 
dithiothreitol (0.1 M), BSA (10 μg), and m7G(5′)ppp(5′)
G cap analogue (1 mM), for 2 h (37 °C). Template was 
degraded by addition of DNase (15 min, 37 °C). Female 
Xenopus laevis frogs were obtained from Xenopus 
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Express (Haute-Loire, France) or Xenopus1 (Michigan, 
USA), killed in accordance with Home Office Schedule 1 
directives, and oocytes isolated, essentially as described 
previously [40, 42]. Oocytes were de-aggregated using 
collagenase A (2.5 mg ml−1, Roche, Burgess Hill, UK) 
in ORII solution and washed in modified Barth’s solu-
tion. Healthy-looking stage V/VI oocytes were manually 
defolliculated as required and stored in modified Barth’s 
solution (18  °C) for approximately 24  h before being 
injected. Oocytes were injected with 50 nl water (control) 
or cRNA (1 μg μl−1) using a Nanoject II automated injec-
tor (Drummond Scientific Company, Broomall, USA) and 
maintained for 2–3 days at 18 °C until use in radiotracer 
transport or two-electrode voltage-clamp (TEVC) assays.
Radiolabelled amino acid transport assays
Radiolabelled amino acid transport (uptake) assays were 
performed, as described previously [42]. In brief, oocytes 
were incubated at room temperature (approximately 
22 °C) in transport solution [100 mM choline chloride 
(or 100 mM NaCl for solutions requiring  Na+), 2 mM 
KCl, 1 mM  CaCl2, 1 mM  MgCl2, 10 mM MES, or HEPES 
adjusted to the required pH with Tris base] containing 
 [3H]- or  [14C]-labelled compound (1–5 μCi ml−1). Assays 
were performed at pH 5.5, in the absence of extracellular 
 Na+, unless stated otherwise. Oocytes were then washed 
three times in ice-cold transport solution and lysed in 10% 
SDS, and the associated radioactivity determined by liquid 
scintillation counting.
Table 1  APC superfamily transporters (as discussed in this paper)
* The TCDB database does not currently list all characterized transporters but includes many examples from different families
Transporter 
(common 
name)
Species or class SLC gene name TCDB number(s)* Example PDB 
number(s) (if crystal-
lised)
Predicted LeuT 
V104-equivalent 
residue
Substrate class
2.A.18 Amino acid/auxin permease (AAAP) family
 PAT2 Mammalia SLC36A2 2.A.18.8.2 (mouse)
2.A.18.8.6 (human)
F159 (rat)
F161 (human)
Amino acid
 CG1139 D. melanogaster I149 Amino acid
 AaePAT1 A. aegypti T167 Amino acid
 ApGLNT1 A. pisum C198 Amino acid
 SNAT5 Mammalia SLC38A5 2.A.18.6.8 (rat)
2.A.18.6.15 (human)
A138 (human) Amino acid
2.A.22 Neurotransmitter:sodium symporter (NSS) family
 LeuT A. aeolicus 2.A.22.4.2 2A65, 3F48 V104 Amino acid
 DAT D. melanogaster 2.A.22.1.7 4XP4 V120 Monoamine
 DAT Mammalia SLC6A3 2.A.22.1.3 (human) V152 (human) Monoamine
 SERT Mammalia SLC6A4 2.A.22.1.1 (human) 5I6X I172 (human) Monoamine
 NET Mammalia SLC6A2 2.A.22.1.2 (human) V148 (human) Monoamine
 CT1 Mammalia SLC6A8 2.A.22.3.11 (human)
2.A.22.3.5 (rat)
2.A.22.3.4 (rabbit)
C144 (human) Creatine
2.A.3 Amino acid-polyamine-organocation (APC) family
 AdiC E. coli 2.A.3.2.5 3L1L, 5J4I G100 Amino acid
 ApcT M. jannaschii 2.A.3.6.3 3GIA S100 Amino acid
 LAT2 Mammalia SLC7A8 2.A.3.8.6 (rat)
2.A.3.8.20 (human)
N133 (mouse)
N134 (human)
Amino acid
 LAT1 Mammalia SLC7A5 2.A.3.8.1 (rat)
2.A.3.8.25 (human)
S144 (human) Amino acid
2.A.39 Nucleobase:cation symporter-1 (NCS1) family
 Mhp1 M. liquefaciens 2.A.39.3.6 4D1A, 2JLN W117 Hydantoin
2.A.30 Cation-chloride cotransporter (CCC) family
 NKCC1 Mammalia SLC12A2 2.A.30.3.1 (human) A379 (human) Electrolyte
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Two‑electrode voltage clamp (TEVC)
Individual oocytes, which had been injected with either 
CG1139 cRNA or water (control), were clamped at 
− 60 mV and superfused with  Na+-free, pH 5.5 transport 
solution (see above), as described previously [42]. Vari-
ous amino acids were added for 1 min and the associated 
inward positive current measured using a Geneclamp 500 
amplifier, Digidata 1200, and pClamp software (Molecu-
lar Devices, Sunnyvale, CA). Compound-associated cur-
rents were calculated by averaging the current during the 
last 15 s of exposure and subtracting the average current 
recorded in the 15 s preceding exposure (baseline). Data 
were analysed using Clampfit 8.2.
Data and statistical analysis
Data are mean ± SEM. and are typically expressed as pmol.
oocyte−1 (uptake duration)−1. Transporter-specific uptake 
was calculated as uptake into transporter-expressing oocytes 
after subtraction of uptake into water-injected oocytes 
(measured under identical conditions). Michaelis–Menten 
kinetics were fitted using GraphPad Prism 6. Comparisons 
b
c
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rat slc36a1
CG12943
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rat slc36a3
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SLC38A10
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of mean values were made by one-way or two-way analy-
sis of variance (ANOVA), as appropriate, with Tukey’s or 
Sidak’s multiple comparisons post-tests (GraphPad Prism 
6). ANOVAs are two-way unless stated otherwise.
Results
LeuT‑fold transporters are highly divergent in their 
overall amino acid sequences
The APC superfamily consists of 18 transporter families [2], 
14 of which are predicted to possess the LeuT-fold 5 + 5 
inverted structural repeat. Phylogenetic sequence analysis 
of prokaryotic and eukaryotic representative members of 
the fourteen families indicates that most are well supported 
as putative monophyletic groups or clans [43] (Fig. 1, sup-
plementary Table S1). The relationships between individual 
families, however, are generally poorly supported high-
lighting the divergent nature of the superfamily as a whole 
(which is also reflected in their differing functions). Six of 
the fourteen families (APC, 2.A.3; AAAP, 2.A.18; AGCS, 
2.A.25; LIVCS, 2.A.26; HAAAP, 2.A.42; PAAP, 2.A.120) 
exclusively contain amino acid transporters. Three families 
(BCCT, 2.A.15; SSS, 2.A.21; NSS, 2.A.22) contain amino 
acid transporters as well as carriers of other substrates. The 
remaining five families contain only other (non-amino acid 
transporting) carriers. Examples of transporters of known 
structure in the APC, SSS, BCCT, NCS1, and NSS families 
[3–12, 14, 15] are denoted in bold in Fig. 1 (see also supple-
mentary Table S1). There appears to be no strong relation-
ship between function and phylogeny underlining the impor-
tance of investigating sequence, structure and function, in 
an integrated manner to understand transport specificity. 
To investigate the importance of the LeuT V104-equivalent 
residue as a molecular determinant of substrate specific-
ity in the APC superfamily we chose, therefore, an exem-
plar amino acid carrier with which to begin our analyses. 
The mammalian proton/amino acid cotransporter PAT2 
(SLC36A2) [39, 40] (asterisk in Fig. 1, see also Table 1) 
is a member of the Amino Acid/Auxin Permease (AAAP, 
2.A.18) family [2, 29] of transporters which are found in 
plants, animals, yeast, and fungi. PAT2 was chosen to sam-
ple an area of the phylogenic tree which has, to date, been 
underexplored and to investigate the generality of the obser-
vations in relation to the APC superfamily as a whole. PAT2 
is a tractable transport protein, amenable to mutagenesis and 
functional measurements. It has a narrow and well-defined 
substrate selectivity that appears to be restricted severely 
by side-chain size [39, 40], identifying it as a suitable can-
didate for functional and mutational analyses. In humans, 
PAT2 contributes to amino acid transport in diverse cell 
types such as renal proximal tubule cells, neurones, and 
adipocytes. Mutations in PAT2 leading to defective func-
tion contribute to the human disorders of iminoglycinuria 
(Online Mendelian Inheritance in Man (OMIM) 242600) 
and hyperglycinuria (OMIM 138500) [44].
Identification of the LeuT V104‑equivalent 
in the AAAP and SLC36 transporter PAT2
The LeuT V104-equivalent residue in PAT2 was identi-
fied by homology modelling and multi-alignment. Consist-
ent results were obtained using a number of programmes 
and APC transporter structures, from different families 
(Fig. 1), as templates (see below and Methods for details). 
Since a substrate’s “best-fit” will likely be represented by 
Fig. 2  Homology modelling predicts that the SLC36 transporter 
PAT2 is a LeuT-fold protein and F159 is equivalent to LeuT V104. a 
PAT2 modelled against the substrate-bound, outward-occluded crys-
tal structure (light grey ribbons) of LeuT bound to leucine (PDB ID 
2A65). Structures are shown from both side-on, within the plane of 
the membrane (left-hand column), and top-down, above the plane 
of the membrane (right-hand column), orientations. The predicted 
PAT2 structures are represented as ribbons in dark grey and in col-
our. The substrate-binding pocket of PAT2 is predicted to be formed 
by TM1 (green), TM3 (blue), TM6 (orange), and TM8 (magenta). 
The comparative models include only TM1-10 (the core 5 + 5) with 
transmembrane domains outside the core LeuT-fold omitted. The sub-
strate, leucine, bound in the crystal structures, is shown as spheres. b 
HHPred alignment of part of TM3 in LeuT, rat PAT2, and D. mela-
nogaster protein CG1139. c Crystal structure of LeuT (light grey) as 
ribbons with the predicted structures of TM3 from rat PAT2 (blue) 
and CG1139 (cyan) superimposed. The side-chains of V104 (LeuT), 
F159 (PAT2) and I149 (CG1139) are shown as sticks. Alanine is 
shown as a substrate (spheres) and was superposed upon the leucine 
backbone bound to the crystal (2A65) using PyMOL. The PAT2 F159 
(blue) and CG1139 I149 (cyan) residues are predicted to restrict the 
volume of the substrate-binding pocket. d Phylogenetic tree, gener-
ated using the CAT20 model in PhyloBayes, showing a cluster of 
SLC36-related invertebrate transporters including CG1139 from D. 
melanogaster. The tree includes all human, and some rodent, AAAP 
(2.A.18) family transporters: SLC36 (blue, rat PAT2 shown in bold); 
SLC32 (which has only one human member); SLC38 (all human 
members included). Invertebrate transporters (cyan) shown are the 
11 D. melanogaster sequences (starting CG, CG1139 shown in bold), 
and the functionally characterized amino acid transporters: AaePAT1 
from A. aegypti and ApGLNT1 from A. pisum (Table 1). The tree is 
outgroup-rooted to the human SLC6 family (part of the NSS (2.A.22) 
family within the APC superfamily). Values at branches represent 
posterior probabilities (scale bar: average number of substitutions 
per site). e–h Homology modelling predicts that PAT2 F159 occu-
pies a structurally homologous position in the binding pocket when 
modelled upon different LeuT-fold transporters. Homology models 
of PAT2 TM3 (blue ribbons, with F159 shown as blue sticks) super-
imposed upon the substrate-bound crystal structures (all light grey 
ribbons) of e arginine (Arg)-bound AdiC (3.0Å resolution, 3L1L), f 
5-indolylmethyl-l-hydantion (I5H)-bound Mhp1 (3.4 Å resolution, 
4D1A), g alanine (Ala)-bound LeuT (1.90 Å resolution, 3F48), and 
h cocaine (Coc)-bound DAT (2.80 Å resolution, 4XP4), demon-
strate that PAT2-F159 occupies a similar position in transmembrane 
domain 3 (TM3) to e AdiC G100 (yellow ribbon), f Mhp1 W117 
(grey sticks), g LeuT V104 (grey sticks), and h DAT V120 (grey 
sticks)
◂
 N. Edwards et al.
1 3
0 2 4 6 8 10
0
50
100
150
200
[Proline] (mM)
C
G
11
39
-s
pe
ci
fic
cu
rre
nt
(n
A)
Control - Na+
0
10
20
30
[3 H
]P
ro
lin
e
up
ta
ke
[p
m
ol
.o
oc
yt
e-
1 .
(4
0m
in
)-1
]
NS
Water CG1139
5 6 7 8
0
5
10
15
20
pH
[3 H
]P
ro
lin
e
up
ta
ke
[p
m
ol
.o
oc
yt
e-
1 .
(4
0
m
in
)-1
]
Water
PAT2
PAT1
CG1139
C
on
tro
l
+A
la
+S
er
+G
ly
+G
AB
A
+P
ro
+M
eA
IB
+C
ys
+T
hr
+S
ar
+V
al
+M
e-
Tr
p
+O
H
-T
rp
+T
rp
+L
eu
+T
yr
+T
au
+M
et
+P
he +I
le
+A
sn
+A
sp
+B
et
+D
M
G
+H
is
+G
ln
+L
ys
+G
lu
+A
rg
0
5
10
15
20
25
Water
CG1139
[3 H
]
-A
la
ni
ne
up
ta
ke
[p
m
ol
.o
oc
yt
e-
1 .
(2
0m
in
)-1
]
NS
*
*******
+D
-A
la
+D
-S
er
+D
-C
ys
+D
-P
ro
+D
-M
et
+D
-L
eu
+
-A
IB
+
-A
BA
+
-A
IB
+
-A
BA
+
-A
la
+
-A
PA
a b
e
1min
50nA
GABA rhTABA- Ser Pro Bet Gly
GABA -ABA Thr Ser Pro Bet Gly
d
0 20 50
0
5
10
15
20
25
30
[FCCP] ( M)
[3 H
]P
ro
lin
e
up
ta
ke
[p
m
ol
.o
oc
yt
e-
1 .
(4
0m
in
)-1
]
*
**
c
f
Gly Pro Ser Thr Leu 
0
10
20
30
[3 H
]A
m
in
o
ac
id
up
ta
ke
[p
m
ol
.o
oc
yt
e-
1 .
(4
0m
in
)-1
]
Water
CG1139
***
***
***
***
NS
Gly GABA MeAIB Tau Gln Met Trp Glu
0.0
0.5
1.0
1.5
2.0
[3 H
]A
m
in
o
ac
id
up
ta
ke
[p
m
ol
.o
oc
yt
e-
1 .
(4
0m
in
)]-
1 ]
Water
CG1139
***
***
***
***
NS NS
NS
NS
NS
***
***
D-Ala D-Ser-Ala
g
h
Resculpting the binding pocket of APC superfamily LeuT-fold amino acid transporters 
1 3
the outward-occluded, substrate-bound, conformation of a 
carrier, PAT2 was initially superimposed on the outward-
occluded, substrate-bound crystal structures of LeuT [pro-
tein data bank (PDB) ID 2A65] [3], AdiC (3L1L) [9], and 
Mhp1 (4D1A) [25] using HHPred and Modeller [34, 35] 
(e.g., Fig. 2a). LeuT V104 (TM3) aligns with the larger, 
aromatic amino acid F159 in rat PAT2 (TM3) (Fig. 2b). 
F159 (rat PAT2) is equivalent to F161 in human PAT2 
(Table 1). LeuT V104 and PAT2 F159 overlap within the 
crystal and predicted structure (Fig. 2c). PAT2 F159 also 
aligns with, and occupies the same locality, as AdiC G100, 
Mhp1 W117, and V104 in the alanine-bound occluded 
LeuT structure (3F48) [28], V120 in the outward-open, 
cocaine-bound, dopamine transporter (DAT) (4XP4) [45] 
(Fig. 2e–h), and S100 in the amino acid transporter ApcT 
(3GIA, not shown) [6] (Table 1). Eight of nine thread-
ing programmes used by I-TASSER [37] align PAT2 
F159 with the same residues in the APC crystal struc-
tures as HHPred. Multi-alignment using PROMALS3D 
[36] identified that V104 (LeuT, 2A65), G100 (AdiC, 
3L1L), W117 (Mhp1, 4D1A), V120 (DAT, 4XP4), and 
S100 (ApcT, 3GIA) align with each other and also with 
F159 in PAT2. The top PAT2 model (by cluster size) in 
I-TASSER had a C score of -1.87 and a TM score of 0.49 
(scores improved to − 0.83 and 0.61 if only the core 5 + 5, 
TM1-10 inclusive, sequence was submitted) [37]. Multi-
ple pairwise structure–structure alignments in Matt [38] 
identified that F159 (in the I-TASSER top PAT2 model), 
V104 (LeuT), G100 (AdiC), and W117 (Mhp1), were in 
equivalent positions, consistent with the predictions from 
I-TASSER, HHPred/Modeller, and PROMALS3D.
To investigate if, and how, the identity of the amino acid 
at the equivalent position to V104 in the LeuT-fold affects 
substrate selectivity in APC superfamily transporters, spe-
cies-scanning mutagenesis [23] was used. In this approach, 
a residue is switched to the equivalent residue of a homolo-
gous transporter from a second species and the effect on 
transport function determined. The Drosophila melanogaster 
transporter CG1139 is found in a cluster of SLC36-related 
transporters (Fig. 2d). CG1139 has 37% sequence identity 
to rat PAT2 (using MUSCLE [30]) making it an appropriate 
comparator for this species-scanning approach as it is likely 
to retain overall mode of function  (H+/amino acid cotrans-
port) [46]. The other AAAP mammalian families (SLC32 
and SLC38) are more distantly related (24% and 20–24% 
identity to PAT2, respectively) (Fig. 2d) and differ in func-
tion to the SLC36 carriers. Homology modelling identifies 
that CG1139 has an isoleucine at position 149 which occu-
pies the equivalent position to PAT2 F159 (and LeuT V104) 
(Fig. 2b, c, Table 1).
The Drosophila melanogaster transporter CG1139 
has broader substrate specificity than mammalian 
SLC36 carriers
The transport of proteinogenic α amino acids via PAT2 is 
limited to proline, glycine, and alanine [39, 40, 42, 47, 48]. 
CG1139 was previously shown to transport alanine (inhib-
ited by glycine and proline) [49]. When modelled upon the 
LeuT amino acid-bound structure, CG1139 I149 occupies 
the same position as PAT2 F159 and LeuT V104 (Fig. 2b, 
c). The reduced volume [50] of the I149 side-chain (relative 
to F159) identifies CG1139 as a suitable model transporter 
for comparison with PAT2 for the investigation of substrate 
selectivity. The difference in volumes occupied by the two 
residues led us to predict that CG1139 would transport α 
amino acids with larger side-chains than those able to access 
PAT2.
CG1139-mediated amino acid transport was first char-
acterized by several complementary measurements (Fig. 3) 
with the essential characteristics being similar to mammalian 
PAT1 and PAT2 transporters [39, 40, 42, 47, 51]. CG1139 
 H+/amino acid transport was  Na+-independent (Fig. 3a), 
pH-dependent (Fig. 3b),  H+ gradient-dependent [reduced by 
FCCP (Fig. 3c)], rheogenic (Fig. 3d, e), and saturable (two-
electrode voltage clamp (TEVC) Km = 0.97 ± 0.15 mM 
Fig. 3  Invertebrate APC transporter CG1139 is a pH-dependent, 
 Na+-independent, amino acid transporter with differing substrate 
specificity to the mammalian SLC36 transporters. a Proline (10 μM) 
uptake (extracellular pH 5.5) in the presence (control) and absence 
(-Na+) of extracellular  Na+ in oocytes injected with CG1139 cRNA. 
Uptake in water-injected oocytes is shown as a control. n = 10; NS 
(not significant), P  >  0.05 vs. control (ANOVA, Tukey’s multiple 
comparisons test). b Proline (10 μM) uptake via CG1139, PAT1, and 
PAT2 at varying extracellular pH in the absence of extracellular  Na+. 
n = 9–10. c CG1139-mediated proline (10 μM) uptake (pH 5.5) in the 
absence and presence of the protonophore FCCP (20–50 µM). n = 10; 
*, P < 0.05; **, P < 0.01 vs. zero FCCP (one-way ANOVA, Tukey’s 
multiple comparisons test). d Amino acid-induced inward currents 
during superfusion with extracellular amino acids (all 10  mM, pH 
5.5,  Na+-free conditions) in two-electrode voltage-clamped oocytes 
(clamped at −  60  mV) injected with either CG1139 cRNA (main 
trace) or water as a control (inset) (representative of 5 and 4 experi-
ments, respectively). ABA, aminobutyric acid; Bet, betaine. e Con-
centration-dependent, proline-induced, CG1139-mediated inward cur-
rent. Data represent current elicited by proline (0.1–10 mM, 1 min) in 
CG1139-expressing oocytes after subtraction of that in water-injected 
oocytes under identical conditions. n = 4. f, g Radiotracer amino acid 
uptake [10 μM (f) and 400 nM (g)] via CG1139 compared to control 
(water-injected oocytes). All amino acids are l-isomers unless stated 
otherwise. MeAIB, α(methylamino)isobutyric acid; Tau, taurine. 
n = 9–10; NS, P > 0.05; ***, P < 0.001 vs. water (ANOVA, Sidak’s 
multiple comparisons test). h β-Alanine (10 μM) uptake measured in 
the absence (control) and presence of amino acids or analogues (all 
10 mM except Tyr which is 2.5 mM). All amino acids are l-isomers 
unless stated otherwise. AIB, aminoisobutyric acid; Sar, sarcosine; 
Me-Trp, α-methyl-d,l-tryptophan; OH-Trp, 5-hydroxy-l-tryptophan; 
APA, aminopentanoic acid; DMG, dimethylglycine. n = 18–20; NS, 
P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001 vs. control (one-
way ANOVA, Sidak’s multiple comparisons test whereby all bars 
were compared to control for CG1139 only)
◂
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for proline (Fig.  3e), and radiotracer proline uptake 
Km = 1.03 ± 0.18 mM).
CG1139 transports the prototypical SLC36 proteino-
genic substrates (alanine, proline, and glycine) and shares 
other SLC36-like characteristics (Fig.  3). The striking 
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difference shown here is that CG1139 also accepts l-amino 
acids with longer side-chains including serine, cysteine, and 
α-aminobutyric acid (α-ABA) (Fig. 3d, f–h). To test whether 
F159 in PAT2 limits access of extended substrate side-chains 
compared to the less bulky CG1139 I149 (Fig. 2c), we 
replaced F159 in PAT2 with isoleucine.
The residue occupying position 159 in PAT2 
determines accessibility of the substrate side‑chain 
within the binding pocket
The large aromatic phenylalanine in PAT2 was replaced 
with the equivalent but smaller isoleucine from CG1139 
(Figs. 2, 4). Like CG1139, but not wild-type PAT2, com-
petition experiments demonstrate that serine, α-ABA and 
cysteine can now access the binding pocket and inhibit 
PAT2-F159I transport (Fig. 4a–e). Larger side-chains are 
excluded from both PAT2 and PAT2-F159I (Fig. 4b). The 
selectivity change in PAT2-F159I is due to improved affin-
ity for serine, α-ABA, and cysteine (all P < 0.001), whereas 
there is a consistent but insignificant decrease (P = 0.054) 
in affinity for proline (Fig. 4c–f). PAT2-F159I not only binds 
Ser and α-ABA but efficiently translocates these amino acids 
(Fig. 4g). In PAT2, proline, glycine, and alanine have Km 
values in the range 120–700 μM [39, 40, 42], whereas serine 
is a very weak substrate. In contrast, the PAT2-F159I Km 
for serine (823 ± 202 μM) is close to that of CG1139 (Km 
1.31 ± 0.12 mM) (Fig. 4h). This change in PAT2 selectivity, 
following F159I mutation to become CG1139-like (Figs. 3, 
4), demonstrates clearly that residue size at position 159 is a 
key determinant of the substrate side-chain that can fit within 
the SLC36 family-binding pocket.
A series of PAT2 mutants, where residue 159 was system-
atically reduced in size (phenylalanine 191.9 Å3, isoleucine 
163.9 Å3, threonine 121.5 Å3, and cysteine 103.3 Å3) [50], 
retained SLC36-like characteristics, transporting proline (the 
gradual decrease in uptake reflecting a decrease in affinity), 
glycine, and alanine (Fig. 5a–e). Methionine is not trans-
ported by CG1139, PAT2, or PAT2-F159I (Fig. 5a, f). The 
increase in hydrophobic-binding pocket volume in PAT2-
F159T allows methionine to inhibit amino acid transport 
(Fig. 5b) without undergoing transport (Fig. 5a), whereas the 
additional space in PAT2-F159C creates a gain-of-function 
phenotype with excellent methionine transport (Fig. 5a, 
f). Titration of the binding pocket volume versus substrate 
side-chain size was accomplished using a series of hydro-
carbon side-chain extended amino acid derivatives from the 
simplest amino acid glycine (no side-chain) to those where 
the side-chain terminal carbon atom is in the beta (Ala), 
gamma (α-ABA), delta (norvaline, NVal), epsilon (norleu-
cine, NLeu), and zeta (2-aminoheptanoic acid, AHA) posi-
tions (Fig. 5c). Glycine and alanine interact with all five 
carriers (Fig. 5c). α-ABA is excluded from PAT2 (Fig. 5c). 
NVal and NLeu are excluded from CG1139, PAT2, and 
PAT2-F159I, but they inhibit amino acid transport via PAT2-
F159T and PAT2-F159C. AHA, containing the longest side-
chain, can only inhibit amino acid transport by the largest 
binding pocket (PAT2-F159C) (Fig. 5c). For natural pro-
teinogenic amino acids, the F159C mutation converts PAT2 
from a carrier with limited space, within the binding pocket 
region associated with the substrate side-chain, to one that 
can transport longer amino acids such as methionine, glu-
tamine and leucine (Fig. 5a, e–f). The general SLC36/PAT2 
pocket mitigates against branching on the β carbon and this 
is retained in PAT2-F159C (relatively weak interaction with 
isoleucine, valine, and threonine) (Fig. 5d, e). PAT2-F159C 
allows access of lysine (with an epsilon-amino group and a 
nitrogen atom in the zeta position) into the binding pocket 
(Fig. 5d). However, the severely reduced rate of transport, 
compared to proline and methionine (Fig. 5f), suggests that 
the charged side-chain is incompatible with translocation. 
A visual summary of the comprehensive transport measure-
ments described (Figs. 3, 4, 5) is presented in Fig. 6.
Our results suggest that the residue occupying the equiva-
lent position to F159 (PAT2) is key to determining substrate 
selectivity in the SLC36 family and related invertebrate 
transporters (Figs. 3, 4, 5). To test whether the role of this 
residue is a common feature across APC superfamily amino 
acid transporters, the investigation was broadened. The 
basis of substrate selectivity was investigated in a distinct 
human AAAP transporter family focussing upon SNAT5 
(SLC38A5), a carrier with very different substrate specific-
ity to PAT2.
Fig. 4  Substitution of F159 in PAT2 with isoleucine, the equiva-
lent residue in CG1139, enables PAT2-F159I to transport amino 
acids with longer side-chains. Amino acid uptake was measured 
in oocytes expressing wild-type PAT2 (PAT2-WT), PAT2 with the 
F159I mutation (PAT2-F159I), or CG1139. Uptake was also meas-
ured in oocytes injected with water as a control. a Proline (10 μM) 
uptake in the absence (control) or presence of serine or α-ABA (both 
5 mM). n = 19–20; NS, P > 0.05; **, P < 0.01; ***, P < 0.001 vs. 
control (ANOVA, Tukey’s multiple comparisons test). b Proline 
(10 μM) uptake in the absence (control) or presence of various unla-
belled amino acids (all 10 mM). Data are expressed as % control (that 
in the absence of unlabelled amino acid). Uptake into water-injected 
oocytes is expressed as % PAT2-F159I control. n  =  17–20; NS, 
P > 0.05; *, P < 0.05; ***, P < 0.001 vs. control (ANOVA, Tukey’s 
multiple comparisons test). c–f Proline uptake in the presence of c 
serine, d α-ABA or e cysteine (all 0–20 mM), or f unlabelled proline 
(0–2 mM). Data are expressed as % control (absence of competitor) 
after the subtraction of uptake into water-injected oocytes. n = 18–20; 
NS, P > 0.05; **, P < 0.01; ***, P < 0.001 vs. PAT2-WT (ANOVA, 
Sidak’s multiple comparisons test). g Uptake of various  [3H/14C] 
amino acids (all 10  μM). n  =  27–30 except α-ABA (n  =  20); NS, 
P > 0.05; *, P < 0.05; ***, P < 0.001 vs. PAT2-WT (ANOVA, Tuk-
ey’s multiple comparisons test). h Concentration-dependent serine 
uptake (0.01–20 mM) by CG1139, PAT-WT, and PAT2-F159I, after 
subtraction of uptake into water-injected oocytes measured under 
identical conditions. n = 18–20
◂
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Fig. 5  Reducing the side-chain volume of the binding pocket residue 
(F159) in PAT2 by substitution to cysteine (F159C) produces a gain-
of-function methionine transporter. Amino acid uptake was meas-
ured in oocytes expressing wild-type PAT2 (PAT2-WT), PAT2 with 
either the F159I, F159T, or F159C mutations, or CG1139. Uptake 
was also measured in oocytes injected with water as a control. a Pro-
line and methionine (both 10 μM) uptake. n = 18–20; NS, P > 0.05; 
*, P  <  0.05; ***, P  <  0.001 vs. water (ANOVA, Tukey’s multiple 
comparisons test). b Amino acid uptake (proline (10 μM) for PAT2-
WT, PAT2-F159I, PAT2-F159T, and CG1139; methionine (10  μM) 
for PAT2-F159C only) measured in the absence (control) or presence 
of excess proline or methionine (10  mM). Uptake in water-injected 
oocytes has been subtracted. n = 10; NS, P > 0.05; ***, P < 0.001 
vs. PAT2-WT (ANOVA, Tukey’s multiple comparisons test). c 
Uptake of proline (10  μM) or methionine (10  μM, PAT2-F159C 
only) measured in the absence (control) or presence of amino acids 
or analogues of increasing side-chain length (all 10  mM). Uptake 
in water-injected oocytes has been subtracted. Numbering on the 
x-axis indicates the number of side-chain carbons within the com-
petitor compound. NVal, norvaline (2-aminopentanoic acid); NLeu, 
norleucine (2-aminohexanoic acid); AHA, 2-aminoheptanoic acid. 
n = 9–10. d  [3H]Amino acid (10 μM) uptake by PAT2-F159C meas-
ured in the absence (control) or presence of excess, unlabelled amino 
acids (all 10 mM). n = 17–20; NS, P > 0.05; ***, P < 0.001 vs. con-
trol (one-way ANOVA, Tukey’s multiple comparisons test whereby 
all bars were compared to control for PAT2-F159C only). e Uptake of 
various amino acids (all 10 µM, extracellular pH 5.5,  Na+-free condi-
tions) into oocytes injected with wild-type PAT2 (PAT2-WT), PAT2-
F159C, or water (as a control). n = 10. NS, P > 0.05; *, P < 0.05; 
***, P  <  0.001 vs. water (ANOVA, Tukey’s multiple comparisons 
test). f Proline, lysine, and methionine uptake (all 10  μM) meas-
ured into wild-type PAT2, PAT2-F159C or water-injected oocytes. 
n  =  19–20. NS, P  >  0.05; *, P  <  0.05; ***, P  <  0.001 vs. water 
(ANOVA, Tukey’s multiple comparisons test)
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In SNAT5 (SLC38A5), A138 is a key molecular 
determinant of substrate specificity
The System N transporter (so-called, because it transports 
amino acids with nitrogen-containing side-chains) SNAT5, 
is a member of SLC38 and the AAAP (2.A.18) family 
(Figs. 1, 2, Table 1) [2, 52]. Although SLC38 and SLC36 are 
more closely related than to other mammalian SLC families 
(Figs. 1, 2), sequence identity is relatively low (e.g., 22%, 
PAT2 vs. SNAT5). SNAT5 functions differently from PAT2 
being an electroneutral amino acid carrier involving  Na+ 
cotransport and  H+ efflux [41, 52]. SNAT5 prefers serine and 
amino acids with longer side-chains (e.g., asparagine and 
glutamine) but only interacts weakly with amino acids with 
shorter side-chains (e.g., alanine and glycine) [40–42, 52]. 
SNAT5 and PAT2 thus exhibit distinctive, almost opposing, 
substrate selectivity.
Comparison of a human SNAT5 homology model with 
the outward-occluded substrate-bound crystal structure of 
LeuT (Fig. 7a) reveals that SNAT5 A138 occupies the equiv-
alent position to LeuT V104 (and thus PAT2 F159) (Fig. 7b, 
c). Serine is transported well by SNAT5, whereas alanine 
is transported poorly (Fig. 7d) [41]. In a reversal of the 
protocol used with PAT2 (Fig. 5), SNAT5 residue 138 was 
mutated and systematically increased in size from alanine 
to phenylalanine (90.0–191.9 Å3) [50], producing A138T, 
A138I, and A138F. Reducing the SNAT5-binding pocket 
volume decreases serine transport in A138T and A138I and 
abolishes transport in A138F (Fig. 7d). The reduction in 
affinity for serine and asparagine (Fig. 7e, f) in A138T and 
A138I indicates that they do not fit as well within the smaller 
binding pocket. In contrast, the A138T and A138I mutants 
gain function and become excellent alanine transporters 
(Fig. 7d) with much improved affinity compared to SNAT5 
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TM6 TM1 
TM3 F159 
α-ABA 
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F159I 
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Fig. 6  Substitution of PAT2 F159 with smaller side-chain residues is 
predicted to enlarge the substrate-binding pocket and concomitantly 
increase access of substrates with elongated side-chains. Predicted 
substrate-binding pocket of PAT2 modelled against the outward-open 
substrate-bound LeuT structure (2A65). Parts of TM1 (grey), TM6 
(grey), and TM3 (blue) are shown as ribbons with potential substrates 
presented as spheres. The side-chain of F159 and related mutants are 
shown as blue spheres (with the oxygen atom of threonine in red and 
the sulphur atom of cysteine in yellow). a, b Prototypical PAT2 sub-
strate alanine (Ala) and the amino acid analogue α-ABA, which is 
excluded from PAT2, are shown in the binding pocket of wild-type 
PAT2. Alanine fits within the pocket, but extension of the side-chain 
by the single methylene group in α-ABA produces a clash with the 
large volume aromatic ring of F159 thus limiting access. c Substitu-
tion of F159 with the smaller side-chain of isoleucine (F159I) permits 
α-ABA access to the PAT2 substrate-binding pocket. d, e Substitu-
tion of F159 with threonine (F159T) is predicted to further increase 
the PAT2 substrate-binding pocket to accommodate NVal but not 
the side-chain extended AHA which clashes with the threonine side-
chain. f Access of AHA to the PAT2 substrate-binding pocket is per-
mitted by a further reduction in the residue side-chain volume by 
substitution of F159 with cysteine (F159C), although some rearrange-
ment of the flexible side-chain is likely required to allow a comforta-
ble fit. Note that the view of the PAT2 substrate-binding pocket in a‑d 
has been rotated by 180º in the horizontal plane in e and f to highlight 
the predicted clash between the side-chains of AHA and F159T. All 
amino acid substrates and analogues were inserted into the binding 
pocket upon the leucine backbone (2A65) using PyMOL
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(Fig. 7g). The affinities for serine and alanine change, such 
that SNAT5 favours serine, the smaller binding pocket of 
A138T appears to take both substrates with similar affinity, 
whereas the even smaller pocket of A138I prefers alanine 
(Fig. 7e–g). Predicted changes in the binding pocket are 
visualised in Fig. 7h–k.
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Fig. 7  Mutation of the LeuT V104 equivalent residue (A138) in the 
System N transporter SNAT5 (SLC38A5) has a striking effect on 
substrate selectivity. a Human SNAT5 modelled against the crys-
tal structure of LeuT (2A65). TM1-TM10 of LeuT are coloured 
light grey. The substrate-binding pocket of SNAT5 is predicted to 
be formed by TM1 (green), TM3 (blue), TM6 (orange), and TM8 
(magenta). The remaining six SNAT5 TMs modelled are coloured 
dark grey (left-hand figure, within the plane of the membrane; right-
hand figure, orientation above the plane of the membrane). For clar-
ity, an extracellular loop (residues 227–247) in SNAT5 has been 
omitted due to a lack of predicted structural homology to LeuT. b 
Partial HHPred alignment of TM3 in LeuT and SNAT5. c Crystal 
structure of LeuT (light grey) with the predicted structure of SNAT5 
TM3 superposed (blue). The side-chains of V104 (LeuT) and A138 
(SNAT5) are shown as sticks. Serine is shown as a substrate (spheres) 
and was inserted into the binding pocket upon the leucine backbone 
using PyMOL. d Serine and alanine (both 50  μM) uptake (at pH 
8.5,  Na+-containing solution) were measured in wild-type SNAT5 
(SNAT5-WT) and the SNAT5 mutants A138T, A138I, A138F. 
n  =  20; NS, P  >  0.05; ***, P  <  0.001 vs. SNAT5-WT (ANOVA, 
Tukey’s multiple comparisons test). e–g Serine uptake (50  μM, pH 
8.5,  Na+) by SNAT5-WT, SNAT5-A138T, and SNAT5-A138I, meas-
ured in the presence of e unlabelled serine, f asparagine, or g alanine 
(all 0–10  mM). Data are expressed as % control (absence of com-
petitor) after the subtraction of uptake into water-injected oocytes. 
n = 9–10; NS, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001 
vs. SNAT5-WT (ANOVA, Tukey’s multiple comparisons test) 
whereby the upper symbols relate to SNAT5-A138I and the lower 
symbols to SNAT5-A138T. h–k Predicted substrate-binding pocket 
of SNAT5 modelled on LeuT with serine as a substrate. The side-
chains of A138 (TM3), A138I and A138F are represented by light 
blue spheres (with the oxygen atom of threonine in red). Substitution 
of A138 with residues with sequentially larger side-chains [threonine, 
A138T (i); isoleucine, A138I (j); phenylalanine, A138F (k)] results 
in a concomitant decrease in the volume of the predicted substrate-
binding pocket which reduces affinity for serine (i, j) (and asparagine) 
or abolishes transport (k)
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Discussion
In all forms of life, transmembrane transfer of nutrients, 
micronutrients, and excretory products is crucial to enable 
homeostasis, adaptation, and optimal cellular performance. 
Amino acid carriers are numerous in nature (see TCDB) 
[1], possess distinct functions, and exhibit dramatic dif-
ferences in substrate specificity. Each cell type expresses 
a unique array of amino acid carriers. For example, the 
mammalian small intestinal epithelial cell expresses at 
least seven amino acid transport systems at the luminal 
surface, eight distinct mechanisms at the basolateral mem-
brane, with many others being expressed in intracellular 
organelles. More than half of the 71 human LeuT-fold 
carriers demonstrate amino acid transport with that num-
ber likely to rise as orphan transporters are characterized 
functionally. Thus, the LeuT-fold is particularly efficient at 
transmembrane movement of amino acids. Each of the 37 
human LeuT-fold amino acid carriers characterized thus 
far demonstrates a unique selectivity, varying greatly in 
substrate specificity and relative affinity. The heterogene-
ity in selectivity, and the currently limited understanding 
of its underlying molecular basis, was the motivation for 
this study. Rather than focussing simply on well-conserved 
residues, we thought it judicious to seek evidence for con-
servation of a discrete position within the LeuT-fold with 
the capacity to influence substrate recognition across the 
APC superfamily.
The properties (spatial, steric, chemical, and electrical) 
of the binding pocket of each transporter are determined 
by main-chain hydrogen bonding partners in the unwound 
regions of TM1 and TM6, along with the side-chains of vari-
ous residues contained primarily within TM1, 3, 6, and 8 
[18]. The principal means by which proteinogenic amino 
acid substrates are differentiated is by side-chain recogni-
tion. The side-chain of the V104 residue forms part of the 
hydrophobic pocket within the LeuT binding site and makes 
van der Waals’ contacts with the aliphatic substrate side-
chain [3]. We hypothesised that the conserved function of 
LeuT V104, and of different amino acid residues occupying 
the equivalent site in other APC superfamily transporters 
(Table 1), is to shape the binding pocket and thus influence 
substrate selectivity.
To test this hypothesis, we studied exemplar mammalian 
carriers from the AAAP (2.A.18) family (within the APC 
superfamily) (Figs. 1, 2, Table 1) that are distinct in func-
tion, substrate specificity, and tissue expression [29, 40, 41, 
52]. The SLC36 carrier, PAT2, is expressed at the human 
renal proximal tubular brush-border membrane where it 
reabsorbs glycine, alanine, and proline [44]. Defective PAT2 
function contributes to iminoglycinuria (OMIM 242600) and 
hyperglycinuria (OMIM 138500) [44]. Other SLC36 carri-
ers play roles in dietary amino acid uptake and in mTORC1 
modulation [29, 51]. The SLC38 member SNAT5, which, 
in contrast, transports amino acids with larger side-chains 
(glutamine, asparagine, and serine), contributes to hepatic 
glutamine influx for protein synthesis, and glutamine efflux 
from astrocytes to support neurotransmitter recycling [52]. 
Other SLC38 carriers are important in amino acid transport 
in the brain, kidney, small intestine, placenta, and skeletal 
muscle [52]. In this investigation, sequential mutation of 
the equivalent residue to LeuT V104 in both PAT2 (F159) 
and SNAT5 (A138) allowed titration of substrate specificity 
based upon amino acid side-chain length (Figs. 3, 4, 5, 6, 7).
The equivalent residue to F159 is conserved within 
mammalian SLC36 transporters but varies in the arthropod 
expansion. The model arthropod carrier CG1139 (which is 
important in fly growth) [49] shares many functional charac-
teristics with mammalian PATs but notably transports amino 
acids with larger side-chains, consistent with having an iso-
leucine rather than phenylalanine at position 149 [the LeuT 
V104-equivalent (Figs. 23, 4, 5)]. In PAT2-F159I, substrate 
selectivity broadened to become more CG1139-like with the 
key-determining factor being the space available within the 
hydrophobic-binding pocket (Figs. 4 and 6). Mutation to 
F159T and F159C decreased residue size, resulting in further 
changes in substrate selectivity, consistent with an increase 
in binding pocket volume enabling access and translocation 
of amino acids with longer side-chains (Fig. 5). Notably, a 
threonine is present at the equivalent position in the Aedes 
aegypti carrier AaePAT1 (Fig. 2, Table 1) which accepts 
amino acids with longer side-chains than alanine and glycine 
[53]. AaePAT1 is highly upregulated in the midgut following 
a blood meal and is responsible for amino acid uptake in the 
yellow-fever mosquito [53]. Similarly, a cysteine is found 
in the aphid Acyrthosiphon pisum transporter ApGLNT1 
(Fig. 2, Table 1) (which sits at the bacteriocyte membrane 
at the symbiotic interface where it supplies glutamine [trans-
ported here by PAT2-F159C (Fig. 5)] to the proteobacterium 
Buchnera aphidicola) [54].
Thus, the homologous residue to LeuT V104 is a key 
determinant of substrate recognition in mammalian SLC36 
(and SLC38) transporters and in more remotely related 
invertebrate carriers.
Furthermore, interpreting published data in the light of 
our work suggest that this site has a much broader and gen-
eral significance for substrate selectivity across the APC 
transporter superfamily. Despite being only distantly related 
(Fig. 1), PAT2 (from the AAAP family) superposes on APC 
superfamily structures from the NSS, APC, and NCS1 fami-
lies (Fig. 2). We find evidence for a role of this equivalent 
residue in substrate selectivity from functional and muta-
tional studies of, mainly non-amino acid transporting, 
members of the SLC6, SLC7, and SLC12 families [22, 24, 
55–62]. In SLC6 transporters from within the NSS (2.A.22) 
family (Fig. 1, Table 1), I172 in the serotonin transporter 
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SERT, V152 in the dopamine transporter DAT (equivalent 
to V120 in the Drosophila DAT crystal structure, 4XP4), 
V148 in the noradrenaline transporter NET, and C144 in the 
creatine transporter CT1 are equivalent to LeuT V104 and 
are predicted to occupy sites close to the binding pockets. 
Even subtle mutations of these residues can modify substrate 
selectivity, affinity, and inhibitor (e.g., selective serotonin 
reuptake inhibitors) binding [22, 24, 55–59, 61]. These func-
tional observations are confirmed in the crystal structures of 
human SERT and Drosophila DAT where the V104-equiv-
alent residues define regions of the binding pockets asso-
ciated with binding of substrates and antidepressants [12, 
15, 45]. Similar observations are made in the APC (2.A.3) 
family which includes the structurally resolved AdiC and 
ApcT as well as the mammalian SLC7 transporters (Fig. 1, 
Table 1). Mutation of N133 in mouse LAT2 (slc7a8), by 
introduction of the LAT1 (SLC7A5)-equivalent residue, to 
produce N133S (corresponding to V104 in LeuT, N134 in 
human LAT2 and S144 in human LAT1), increases 3,3-dii-
odothyronine (T2) transport [62]. In the CCC (2.A.30) fam-
ily, mutation of the V104 equivalent residue (A379) in the 
bumetanide-sensitive NKCC1 (SLC12A2) (Fig. 1, Table 1), 
a  Na+/K+/2Cl− cotransporter important in human fluid and 
electrolyte secretion and homeostasis, demonstrates that 
side-chain size was inversely related to 86Rb+ flux, and 
affinities for sodium and chloride were reduced compared 
to wild-type [60]. In the NCS1 (2.A.39) family (Fig. 1, 
Table 1), W117 in Mhp1 is conserved among all other mem-
bers [5]. The indole ring of tryptophan forms a pi-stacking 
interaction with the hydantoin moiety of the Mhp1 substrate 
and presumably performs a similar function in other family 
members as all substrates contain ring structures [25]. Thus, 
the data reported here, supported by published data from a 
variety of eukaryote and prokaryote transporters, confirm 
that the residue occupying the equivalent position to LeuT 
V104 is important in determining substrate selectivity, in 
both amino acid transporters and other carriers, across the 
APC superfamily (Fig. 1, Table 1).
Amino acid transporters and other solute carriers (SLCs) 
are involved in many key physiological processes and, as 
such, are drug targets for treatment of numerous disease 
states [18, 20, 63]. In addition, SLCs are integral determi-
nants of drug disposition as therapeutic agents can hijack 
transporters [64]. Thus, numerous prokaryotic and eukary-
otic transporters are potential targets in overcoming disease-
causing mutations, targeting disease-causing vectors, and 
improving drug delivery and agricultural yield. Realistically, 
we cannot determine the structure and function of all trans-
porters throughout the kingdoms of life, particularly as the 
number of potential targets increases daily. Rather, accu-
rate in silico modelling and predictive methods of function 
are something of a “holy grail”. Such methodologies are 
being used currently with some success in the identification 
of novel substrates for specific SLCs [65]. However, for 
rational approaches to novel drug design and treatment of 
disease states to be developed, and for such predictive mod-
elling strategies to be successful, extensive knowledge and 
understanding of both structure and function of archetypal 
membrane transporters are required. Judging by the large 
number of distinct amino acid transporters in the APC super-
family (see TCDB) [1], the LeuT-fold appears particularly 
well adapted for the translocation of amino acids. Here, 
we show, through comprehensive functional studies, that a 
single divergent residue position is a principal molecular 
determinant of substrate specificity in LeuT-fold amino acid 
transporters. The V104-equivalent residue is an important 
piece of the puzzle which, along with future studies of both 
dynamic (functional) and static (structural) states, will ena-
ble construction of an accurate 3D functional map of the 
APC superfamily LeuT-fold.
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